OUR GROUP OUR HEALTHCARE OFFERING OUR AREAS OF EXPERTISE OUR COMMITMENTS NEWSROOM CAREERS PARTNERING PRESS ANNUAL REPORT FR MEDIATOR INFORMATION OUR DEVELOPMENT PORTFOLIO Updated September 2021 ONCOLOGY CARDIOMETABOLISM NEUROSCIENCE IMMUNO-INFLAMMATION PHASE 1 Haematological malignancies Mcl1 inhibitor Haematological malignancies Bcl2 inhibitor Haematological malignancies DHODH inhibitor Solid tumors Anti CD73 Solid tumors MAT2A inhibitor Solid tumors NKG2A Solid tumors PDLx41 BB Solid tumors Anti PD1xAnti TIM3 Relapsed or refractory myelodysplastic syndrome (MDS) Tibsovo® (pre-registration) Grade 2-3 Gliome, combo Vorasidenib PHASE 2 Sjögren disease Anti IL7R PHASE 3 Colorectal cancer, 1st line Combo Lonsurf® Colorectal cancer, 3rd line Combo Lonsurf® Colorectal cancer Anti EGFR combo Lonsurf® Acute myeloid leukemia (AML) IC-ineligible, 1st line Tibsovo® Acute myeloid leukemia (AML) IC-eligible, 1st line Tibsovo® Low-grade Glioma Vorasidenib TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES